3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
9
Stomach Neoplasms
8
Carcinoma, Hepatocellular
8
Neoplasm Metastasis
7
Triple Negative Breast Neoplasms
6
Rectal Neoplasms
6
Nasopharyngeal Carcinoma
6
Melanoma
6
Lymphoma, Extranodal NK-T-Cell
6
Locally Advanced Rectal Cancer
6
Colorectal Neoplasms
6
Carcinoma, Renal Cell
6
Squamous Cell Carcinoma of Head and Neck
5
Sarcoma
5
Pancreatic Neoplasms
4
Uterine Cervical Neoplasms
3
Small Cell Lung Carcinoma
3
Cholangiocarcinoma
3
Thyroid Neoplasms
2
Nasopharyngeal Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Kidney Neoplasms
2
Hemangiosarcoma
2
Gastrointestinal Stromal Tumors
2
Esophageal Squamous Cell Carcinoma
2
Esophageal Neoplasms
2
Adenocarcinoma Of Esophagus
2
Uveal Melanoma
1
Urinary Bladder Neoplasms
1
Turcot syndrome
1
Interventions
Ipilimumab
5
Radiotherapy
4
Nivolumab
4
Doxorubicin
4
CTLA-4 Antigen
4
pembrolizumab
3
Gemcitabine
3
cabozantinib
2
brostallicin
2
Sunitinib
2
Specimen Handling
2
Radiation Dose Hypofractionation
2
Radiation
2
Magnetic Resonance Spectroscopy
2
Ifosfamide
2
Docetaxel
2
Biopsy
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
tremelimumab
1
toripalimab
1
talimogene laherparepvec
1
spartalizumab
1
soblidotin
1
sintilimab
1
saracatinib
1
romidepsin
1
reolysin
1
perifosine
1
pazopanib
1
fludarabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Histiocytoma, Malignant Fibrous
×
spartalizumab
×
Clear all
NCT05961761
2023-07-27
PROPANE
Herlev and Gentofte Hospital
Phase 2
Recruiting
80 enrolled